ReviewCurrent pharmaceutical design2026
Development of Novel Approaches for the Treatment of Cutaneous Candidiasis.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main culprit behind cutaneous candidiasis, a fungal infection that can lead to major dermatological and systemic health problems, is Candida albicans. Over the past 20 years, cutaneous candidiasis has become more prevalent, especially in hospitalized or immunocompromised patients. Conventional treatment methods employ antifungal drugs like azoles and polyenes, which are effective but have drawbacks because of their high recurrence rates, negative side effects, and growing antifungal resistance. This study highlights recent advancements in novel treatment techniques for cutaneous candidiasis. New antifungal medications that more precisely target specific fungal pathways, including echinocandins and triazole derivatives, are examples of emerging techniques. The most common symptoms are interdigital candidiasis, cheilitis, intertrigo, and diaper dermatitis, but they can occur elsewhere in the body. Other types of Candida may be the reason for infections that occur from person to person, even though C. Candida albicans is the most frequent culprit. The most typical signs of Candida infections are burning and tingling. Skin symptoms might vary, in any case. The two main signs of candidiasis are bright erythema and skin erosions with satellite pustules. Yeast is the main cause of cutaneous candidiasis. Candida, especially Candida albicans, is characterized by epidermal exposure of the skin, nails, interdigital space, and mucous membranes. This study discusses several species of
Indexed as
Identifiers
40910200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.